研究者詳細 - 赤塚　美樹

論文 - 赤塚　美樹

分割表示 93 件中 1 - 20 件目／全件表示 >>

特集 CAR-T細胞療法の最前線--現状と残された課題はじめに

赤塚美樹

医学のあゆみ 288 巻 ( 3 ) 頁： 181 - 181 2024年1月

Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation 査読有り国際誌

Barakat Carolyne, Inagaki Yuichiro, Mizuno Shohei, Nishio Nobuhiro, Katsuyama Naoya, Sato Yoshie, Kobayashi Miki, Ozeki Kazutaka, Iida Hiroatsu, Tomita Akihiro, Sawa Masashi, Demachi-Okamura Ayako, Takahashi Yoshiyuki, Nishikawa Hiroyoshi, Akatsuka Yoshiki

INTERNATIONAL JOURNAL OF HEMATOLOGY 118 巻 ( 2 ) 頁： 252 - 266 2023年8月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：International Journal of Hematology

Relapsed leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a significant challenge, with the re-emergence of the primary disease being the most frequent cause of death. Human leukocyte antigen (HLA)-DPB1 mismatch occurs in approximately 70% of unrelated allo-HSCT cases, and targeting mismatched HLA-DPB1 is considered reasonable for treating relapsed leukemia following allo-HSCT if performed under proper conditions. In this study, we established several clones restricted to HLA-DPB1*02:01, -DPB1*04:02, and -DPB1*09:01 from three patients who underwent HLA-DPB1 mismatched allo-HSCT using donor-derived alloreactive T cells primed to mismatched HLA-DPB1 in the recipient’s body after transplantation. A detailed analysis of the DPB1*09:01-restricted clone 2A9 showed reactivity against various leukemia cell lines and primary myeloid leukemia blasts, even with low HLA-DP expression. T cell receptor (TCR)-T cells derived from clone 2A9 retained the ability to trigger HLA-DPB1*09:01-restricted recognition and lysis of various leukemia cell lines in vitro. Our study demonstrated that the induction of mismatched HLA-DPB1 specific T cell clones from physiologically primed post-allo-HSCT alloreactive CD4+ T cells and the redirection of T cells with cloned TCR cDNA by gene transfer are feasible as techniques for future adoptive immunotherapy.

DOI： 10.1007/s12185-023-03621-y

Web of Science

Scopus

PubMed

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens 招待有り査読有り国際誌

Akatsuka Yoshiki

FRONTIERS IN IMMUNOLOGY 11 巻頁： 257 - 257 2020年2月

Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. 査読有り

Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A, Tsujikawa J, Demachi-Okamura A, Hiramatsu K, Saji H, Yamamoto Y, Yamamoto N, Nishimura Y, Takahashi T, Kuzushima K, Emi N, Akatsuka Y

Gene therapy 21 巻頁： 575-584 2014年6月

HapMap scanning of novel human minor histocompatibility antigens. 査読有り

Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y, Takahashi T, Yazaki M, Morishima S, Tsujimura K, Miyamura K, Ito T, Togari H, Riddell SR, Kodera Y, Morishima Y, Takahashi T, Kuzushima K, Ogawa S, Akatsuka Y

Blood 113 巻頁： 5041-5048 2009年5月

Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. 査読有り

Kawase T, Nannya Y, Torikai H, Yamamoto G, Onizuka M, Morishima S, Tsujimura K, Miyamura K, Kodera Y, Morishima Y, Takahashi T, Kuzushima K, Ogawa S, Akatsuka Y

Blood 111 巻頁： 3286-3294 2008年3月

Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. 査読有り

Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, Tsujimura A, Miyazaki M, Tsujimura K, Miyamura K, Ogawa S, Inoko H, Morishima Y, Kodera Y, Kuzushima K, Takahashi T

Blood 110 巻頁： 1055-1063 2007年8月

A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. 査読有り

Torikai H, Akatsuka Y, Miyazaki M, Warren EH 3rd, Oba T, Tsujimura K, Motoyoshi K, Morishima Y, Kodera Y, Kuzushima K, Takahashi T

Journal of immunology (Baltimore, Md. : 1950) 173 巻頁： 7046-7054 2004年12月

The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. 査読有り

Brickner AG, Warren EH, Caldwell JA, Akatsuka Y, Golovina TN, Zarling AL, Shabanowitz J, Eisenlohr LC, Hunt DF, Engelhard VH, Riddell SR

The Journal of experimental medicine 193 巻頁： 195-206 2001年1月

T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation 査読有り

Katsuyama N, Kawase T, Barakat C, Mizuno S, Tomita A, Ozeki K, Nishio N, Sato Y, Kajiya R, Shiraishi K, akahashi Y, Ichinohe T, Nishikawa H, Akatsuka Y

Nagoya J Med Sci 85 巻 ( 7 ) 頁： 779 - 796 2023年11月

CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma 査読有り国際誌

Okamoto Akinao, Fujigaki Hidetsugu, Iriyama Chisako, Goto Naoe, Yamamoto Hideyuki, Mihara Keichiro, Inaguma Yoko, Miura Yasuo, Furukawa Katsuya, Yamamoto Yukiya, Akatsuka Yoshiki, Kasahara Senji, Miyao Kotaro, Tokuda Masutaka, Sato Seiko, Mizutani Yuki, Osawa Michiko, Hattori Keiko, Iba Sachiko, Kajiya Ryoko, Okamoto Masataka, Saito Kuniaki, Tomita Akihiro

BLOOD ADVANCES 6 巻 ( 11 ) 頁： 3230 - 3233 2022年6月

A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients 査読有り

Chen Shurui, Kiguchi Toru, Nagata Yasuyuki, Tamai Yotaro, Ikeda Takeshi, Kajiya Ryoko, Ono Takaaki, Sugiyama Daisuke, Nishikawa Hiroyoshi, Akatsuka Yoshiki

INTERNATIONAL JOURNAL OF HEMATOLOGY 2021年1月

Improving TCR affinity on 293T cells 査読有り国際誌

Ohta Rieko, Demachi-Okamura Ayako, Akatsuka Yoshiki, Fujiwara Hiroshi, Kuzushima Kiyotaka

JOURNAL OF IMMUNOLOGICAL METHODS 466 巻頁： 1 - 8 2019年3月

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

Leukemia 2019年1月

[Progress in immune checkpoint inhibitor therapies].

Akatsuka Y

[Rinsho ketsueki] The Japanese journal of clinical hematology 60 巻 ( 9 ) 頁： 1341 - 1350 2019年

記述言語：日本語出版者・発行元：一般社団法人日本血液学会

<p>世界初の免疫チェックポイント阻害抗体であるiplimumabが転移性悪性黒色腫に対してアメリカ食品医薬品局（FDA）により2011年に承認されてからすでに8年が経過した。この間に複数の免疫チェックポイント阻害剤が開発され，悪性黒色腫を含む数種のがんに対して承認を受けてきたが，問題点も浮かび上がってきた。すなわち単独投与での奏効率が多くのがんで30％を超えないこと，免疫チェックポイント阻害剤2剤併用療法では奏効率は上がるものの免疫関連有害事象も重篤化することである。このため，投与後の臨床検体を用いたリバーストランスレーション研究が精力的になされ，耐性機序や治療効果が期待できる患者を選択できるバイオマーカーが徐々に解明されるとともに，新たな併用療法への開発が進んできた。本稿ではがん免疫の基礎を踏まえつつ，免疫チェックポイント阻害剤耐性機序の解明とその克服に向けた最近の知見を概説する。</p>

DOI： 10.11406/rinketsu.60.1341

PubMed

Comparison of the tube test and column agglutination techniques for anti-A/-B antibody titration in healthy individuals. 査読有り国際誌

Matsuura H, Akatsuka Y, Matsuno T, Sugiura Y, Arakawa S, Oikawa S, Yoshida J, Kosugi M, Emi N

Vox sanguinis 113 巻 ( 8 ) 頁： 787 - 794 2018年11月

Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H

Blood 132 巻 ( 11 ) 頁： 1134 - 1145 2018年9月

Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1–RUNX1T1 leukemia with t(8;12;21) 査読有り国際誌

Akihiro Abe, Yukiya Yamamoto, Akira Katsumi, Akinao Okamoto, Masutaka Tokuda, Yoko Inaguma, Kiyoko Yamamoto, Masamitsu Yanada, Tadaharu Kanie, Akihiro Tomita, Yoshiki Akatsuka, Masataka Okamoto, Toshiki Kameyama, Akila Mayeda, Nobuhiko Emi

International Journal of Hematology 108 巻 ( 2 ) 頁： 208 - 212 2018年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

© 2017, The Japanese Society of Hematology. Variant chromosomal translocations associated with t(8;21) are observed in 3–4% of acute myeloid leukemia (AML) cases with a RUNX1–RUNX1T1 fusion gene. However, the molecular events that occur in variants of t(8;21) are not well characterized. In the present study, we report genetic features of a variant three-way translocation of t(8;12;21)(q22;p11;q22) in a patient with AML. In this patient, leukemia cells lacked azurophilic granules, which does not correspond with the classic features of t(8;21). RNA-seq analysis revealed that TM7SF3 at 12p11 was fused to VPS13B at 8q22 and VPS13B to RUNX1, in addition to RUNX1–RUNX1T1. VPS13B was located near RUNX1T1 and both were localized at the same chromosomal bands. The reading frames of TM7SF3 and VPS13B did not match to those of VPS13B and RUNX1, respectively. Disruption of VPS13B causes Cohen syndrome, which presents intermittent neutropenia with a left-shifted granulopoiesis in the bone marrow. Disruption of VPS13B may thus cause the unusual features of RUNX1–RUNX1T1 leukemia. Our case indicates that rearrangement of VPS13B may be additional genetic events in variant t(8;21).

DOI： 10.1007/s12185-017-2387-x

Scopus

PubMed

Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. 査読有り国際誌

Espinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, Nakagawa N, Zaimoku Y, Imi T, Hassanein HA, Khalifa A Noreldin A, Takenaka K, Akashi K, Hamana H, Kishi H, Akatsuka Y, Nakao S

Blood advances 2 巻 ( 4 ) 頁： 390 - 400 2018年2月

Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia A case report and literature review 査読有り国際誌

Harada Yasuhiko, Nishiwaki Satoshi, Sugimoto Takumi, Onodera Koichi, Goto Tatsunori, Sato Takahiko, Kamoshita Sonoko, Kawashima Naomi, Seto Aika, Okuno Shingo, Yamamoto Satomi, Iwasaki Toshihiro, Ozawa Yukiyasu, Miyamura Koichi, Akatsuka Yoshiki, Sugiura Isamu

MEDICINE 96 巻 ( 50 ) 頁： e9160 2017年12月

　前のページ - 次のページ　

<赤塚 美樹>

論文 - 赤塚 美樹

<赤塚　美樹>

論文 - 赤塚　美樹